Pharmacodynamic of Recombinant Human Interferon Alpha-2b Nasal Drops and Effective Prophylaxis Against SARS-COV-2 Infection
- 1 June 2024
- journal article
- research article
- Published by SAGE Publications in Journal of Interferon & Cytokine Research
- Vol. 44 (6) , 271-280
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Nonsteroidal anti‐inflammatory drugs in acute viral respiratory tract infections: An updated systematic reviewPharmacology Research & Perspectives, 2022
- Nasalferon, a new nasal formulation of IFNα2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and bloodClinical Immunology Communications, 2022
- Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive reviewCytokine & Growth Factor Reviews, 2022
- Interferon‐alpha position in combating with COVID‐19: A systematic reviewJournal of Medical Virology, 2021
- Antiviral activities of type I interferons to SARS-CoV-2 infectionAntiviral Research, 2020
- Household transmission of SARS-CoV-2Journal of Infection, 2020
- From SARS and MERS CoVs to SARS‐CoV‐2: Moving toward more biased codon usage in viral structural and nonstructural genesJournal of Medical Virology, 2020
- Global virus outbreaks: Interferons as 1st respondersSeminars in Immunology, 2019
- Respiratory Viruses2018
- WHO-adverse reaction terminology (WHO-ART)2009